Clinical Trial

A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this clinical study is to find out how the novel insulin NNC0363-1063 and a non-glucose carbohydrate used in food and beverage might interact in participants with type 1 diabetes and if co-administration of these substances is safe and tolerable. All participants will get a fixed dose of NNC0363-1063 and an oral administration of different amounts of the non-glucose carbohydrate in a random order during 4 interaction tests. The participants will be in this clinical study for about 5 to 12 weeks.
Protocol Amendment History 1 change
critical Trial completed 2026-06-06
Trial Details
NCT Number NCT07305805
Lead Sponsor Novo Nordisk A/S
Conditions Diabetes Mellitus, Type 1
Enrollment 36 participants
Start Date 2025-12-16
Primary Completion 2026-04-21 (estimated)
Study Completion 2026-05-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-05